

# Losar Tablets

Losartan potassium 50 mg

## Composition:

Each tablet contains 50 mg of Losartan potassium

## Properties:

\* Losar (Film coated tablet) contains Losartan potassium 50 mg as an active ingredient, which is a new class of anti-hypertensive and an effective synthetic, orally active angiotensin II receptors antagonist. Angiotensin II (a potent vasoconstrictor) is the active hormone of renin angiotensin system and a major determinant in the Pathophysiology of hypertension.

\* Angiotensin II also stimulates smooth muscle cell proliferations.

\* Losar and its principal active metabolites block the vasoconstriction effect of aldosterone secretion effects of angiotensin II to the AT1 receptor round in many tissues (e.g. vascular smooth muscle, adrenal gland, kidneys, and the heart).

\* Losar also doesn't exhibit any partial agonist activity at At2 receptor.

" Neither Losar nor its metabolites inhibits ACE nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.

## Indication:

'Treatment of hypertension, alone or in combination with other antihypertensives.

## Dosage and method of administration:

\* Losar can be taken during or after meals.

\* Losartan 50 mg is the starting and maintenance dose, the dose can be increased to 100 mg /day to get satisfactory response in some patients. 'There is no need for initial dosage adjustment with Losar, **and** also in elderly people or patients with renal impairments.

## Contraindication:

Losar is contraindicated in-patients who are hypersensitive **to** any component of this product.

## Special warning and precautions:

### 'Symptomatic hypotension:

In patients who are intra-vascularly volume-depleted, symptomatic hypotension may occur. Such situations are most likely in patients with concurrent cardiac insufficiency there may be an increased risk of symptomatic hypotension and also in patients suffer from aortic stenosis in such patients treatment should be initiated at hospitals.

### \* Hepatic impairment:

Lower dose of Losar should be considered for hepatic impairment patients.

### \* Renal artery stenosis:

In such patients, **renal monitoring after initiation of treatment is** advised. 'Surgery and anaesthesia:

If anaesthesia causes hypotension, correct by volume replenishment.

### \*Patient under hemodialysis:

Lower dose of Losar should be considered.

### \* Paediatric use:

Losar has not been studied in children.

**Drug interactions:**

\* The use of Losar with other anti-hypertensives may potentiate the anti-hypertensive effect. When given together with thiazide-type diuretics, the blood pressure lowering effects of Losar are approximately additive.

\* No drug -drug interactions of clinical significant have been identified These drugs, which studied in clinical pharmacokinetic trials, include Hydrochlorothiazide, Digoxin, Warfarin, Cimetidine and Phenobarbitone.

**Side effects:**

\* Dizziness was the only side effect reported as drug related that occur with an incidence greater than placebo in one or more of patients treated with Losar.

\*Dose related orthostatic hypotension were seen in less than one percent of patients treated with Losar.

**Package:**

Box of 7 tablets

**Produced by :**

**UNI PHARMA**

EL OBOUR CITY, CAIRO - EGYPT